|Bid||0.2316 x 1400|
|Ask||0.2320 x 1200|
|Day's Range||0.2301 - 0.2465|
|52 Week Range||0.2100 - 2.5400|
|Beta (5Y Monthly)||0.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2022 - Nov 18, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
Subscribe to Yahoo Finance Plus to view Fair Value for VBLT
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and 57.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Exploring strategic options to maximize shareholder value; engaged Chardan as financial advisorTEL AVIV, Israel and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced financial results for the second quarter ended June 30, 2022 and provided a corporate update. “Following our announcement in July that the Phase 3 OVAL trial evaluating ofra-vec did not meet its primary
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.